within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M04A_AntigoutPreparations.M04AB05_Lesinurad;

model Lesinurad
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 1.8333333333333333e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.04,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016,
    Tlag = 10.200000000000001,
    Vdp = 0.038,
    k12 = 3.0277777777777776e-06,
    k21 = 3.0277777777777776e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lesinurad</td></tr><tr><td>ATC code:</td><td>M04AB05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lesinurad is a selective uric acid reabsorption inhibitor (SURI) used in combination with xanthine oxidase inhibitors to treat hyperuricemia associated with gout. It acts by inhibiting the uric acid transporter URAT1 in the kidneys, thereby increasing uric acid excretion. It was approved for use but has since been withdrawn from the market in several countries due to business reasons rather than safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from studies in healthy adult subjects, single oral dose of 200 mg under fasting conditions.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M04AB05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lesinurad;
